Women should decide which conditions matter

Area of Science:

• Obstetrics and Gynecology
• Medical Genetics
• Fetal Medicine

Background:

• Prenatal screening for aneuploidy is essential for patient counseling and policy.
• Sequential screening (serum and ultrasound) is a common primary test.
• Cell-free DNA (cfDNA) screening is a newer, noninvasive secondary option.

Discussion:

• Both sequential and cfDNA screening are noninvasive and detect common aneuploidies.
• cfDNA screening identifies more common chromosome abnormalities like trisomy 21.
• Sequential screening detects other aneuploidies (e.g., triploidy) and fetal structural abnormalities.

Key Insights:

• Accurate performance estimates are critical for informed patient choices.
• Comparison of sequential and cfDNA screening requires careful consideration of detection rates and biases.
• cfDNA may become a primary screening alternative with future cost reductions.

Outlook:

• Further research is needed to refine performance estimates for both screening methods.
• Understanding the proportion and severity of identified abnormalities is key.
• Standardized reporting of detection rates, accounting for biases, is crucial for clinical practice.